← All trials
NCT00935168
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2009
- Primary completion
- Apr 1, 2012
- Completion date
- Sep 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 7000
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of New South WalesLead sponsor
- University of SydneyCollaborator
- FreseniusCollaborator
- Bendigo Health, VIC, AustraliaOverall official - principal investigator
- University of MelbourneOverall official - principal investigator
- Western Hospital, Footscray, Victoria. AustraliaOverall official - principal investigator
- University of New South WalesOverall official - principal investigator
- University of QueenslandOverall official - principal investigator
- University of AucklandOverall official - principal investigator
- The Northen Hospital, VIC, AustraliaOverall official - principal investigator
- Tauranga Hospital, New ZealandOverall official - principal investigator
- North Shore Hospital, New ZealandOverall official - principal investigator
- Royal Hobart Hospital, TAS, AustraliaOverall official - principal investigator
- Geelong Hospital, AustraliaOverall official - principal investigator
- Wesley Hospital, KogarahOverall official - principal investigator
- University of SydneyOverall official - principal investigator
- Monash UniversityOverall official - principal investigator
- University of Western AustraliaOverall official - principal investigator
- University of OtagoOverall official - principal investigator
- Australian and New Zealand Intensive Care Society Clinical Trials GroupCollaborator
- Rush UniversityOverall official - principal investigator
- Mater Centre - South BrisbaneOverall official - principal investigator
- Waikato HospitalOverall official - principal investigator
- Australian National UniversityOverall official - principal investigator
- University of New South WalesStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.